Gene
MAP2K2
MAP2K2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (9), Actionable biomarkers (4), Trial mentions (15), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MAP2K2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 10 of 11,460 | 0.09% |
| 2022 | 1 of 8,285 | 0.01% | 2 of 13,598 | 0.01% |
| 2021 | 1 of 8,692 | 0.01% | 12 of 15,045 | 0.08% |
| 2020 | 3 of 7,640 | 0.04% | 8 of 14,459 | 0.06% |
| 2019 | 1 of 7,300 | 0.01% | 13 of 12,159 | 0.11% |
| 2018 | 2 of 6,927 | 0.03% | 14 of 11,854 | 0.12% |
| 2017 | 0 of 6,558 | 0.00% | 10 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (9)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| ReSyn Biosciences | Reagent supplier | Clinical validationAnalytical validation | 1 | July 01, 2025 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 1 | July 01, 2025 |
| Dana-Farber Cancer Institute | Not a company | Clinical validation | 1 | April 01, 2015 |
| Genentech | Pharma or other | Clinical validation | 1 | April 01, 2015 |
| Memorial Sloan Kettering Cancer Center | Not a company | Clinical validation | 1 | April 01, 2015 |
Showing 5 of 9 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MAP2K2 (V35M,L46F,N126D,C125S) | Mek Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
| MAP2K2 (Q60P) | Braf Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
| MAP2K2 (V35M,L46F,N126D,C125S) | Braf Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
| MAP2K2 (Q60P) | Mek Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
Trial mentions (15)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05554328 | Trial eligibility (AACT) |
| NCT04219007 | Trial eligibility (AACT) |
| NCT04888936 | Trial eligibility (AACT) |
| NCT04286360 | Trial eligibility (AACT) |
| NCT06411821 | Trial eligibility (AACT) |
Showing 5 of 15 trial mentions.
Target-disease associations (279)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal facial shape | phenotype | Variant curation (ClinVar / EVA) |
| Abnormality of the cardiovascular system | phenotype | Variant curation (ClinVar / EVA) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 279 associations.
Vendor sourcing (53)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with supporting evidence (ClinVar ID:... | View ClinVar record SCV002011936.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The MAP2K2 c.712C>T; p.Arg238Trp variant (rs1233377512), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID... | View ClinVar record SCV004564323.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein ... | View ClinVar record SCV002606887.2 |
| Andrew Dauber | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Parent(s) or guardian(s) are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to... | View trial NCT04219007 |
| Andrew Dauber | Trial sponsor | Mentioned in trial textTrial free-text mention | MAP2K2 | View trial NCT04219007 |
Showing 5 of 53 sourcing records.
Trial-cited literature (129)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. | BMC cancer | 2024 | 6 |
| Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. | Nature medicine | 2023 | 270 |
| Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. | Cancers | 2023 | 89 |
| Colorectal cancer and therapy response: a focus on the main mechanisms involved. | Frontiers in oncology | 2023 | 30 |
| ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. | BMC cancer | 2023 | 28 |
Showing 5 of 129 papers.
Protein variant mentions (26)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A272T | 1 | 2015 | PMID 25741868 |
| p.D151E | 1 | 2015 | PMID 25741868 |
| p.D221N | 1 | 2015 | PMID 25741868 |
| p.E48G | 1 | 2015 | PMID 25741868 |
| p.E73K | 1 | 2015 | PMID 25741868 |
Showing 5 of 26 variants.
Literature-extracted relations (16)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Poly IC | Chemical | associate |
Differential Inflammatory-Response Kinetics of Human Keratinocytes upon Cytosolic RNA- and DNA-Fragment Induction. | 2018 |
| SIMVASTATIN | Chemical | associate |
Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. | 2016 |
| ADENOSINE TRIPHOSPHATE | Chemical | associate |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. | 2014 |
| CURCUMIN | Chemical | associate |
The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. | 2008 |
| MELATONIN | Chemical | associate |
Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. | 2006 |
Showing 5 of 16 relation assertions.
Organizations publishing (178)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 11 | 2014 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 9 | 2012 to 2021 |
| The University of Texas System | Academic | 9 | 2013 to 2023 |
| Dana-Farber Cancer Institute | Other | 6 | 2013 to 2023 |
| The Netherlands Cancer Institute | Hospital | 5 | 2015 to 2023 |
Showing 5 of 178 organizations.
Where MAP2K2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- nervous system disease
- phenotype
- respiratory or thoracic disease
240 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.